

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants ‡ <i>Prediction of Cancer Therapeutics Related Cardiac Dysfunction and Major Adverse Cardiovascular Events in Cancer patients treated with potentially Cardiotoxic Agents</i>	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
BridgeBio	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Myocardial Solutions	Research/Research Grants ‡ <i>PROACT</i>	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (5)

Trial Name	Trial Sponsor	Trial Funding Source
DepleTTR	Alexion/AstraZeneca	
Triton	Alnylam	
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)	Eidos Therapeutics	
Magnitude	Intellia	
Cardio-TTRansform	Ionis	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2025	Maureen Lewis as Independent Executor of the Estate of Steven H. Lewis, deceased v. Orchard Group, Inc. d/b/a Orchard Medical Group and Anuj Lal, M.D. Circuit Court of Cook County Case No. 2023 L 9763	Defendant	Patient died from myocardial rupture during stress test. Amyloid deposits were found at the site of the rupture.	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/6/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/6/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

On-Going Obligation Agreement | Signed on 9/6/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.